NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 08/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About Ayala Pharmaceuticals Stock (NASDAQ:ADXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ayala Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.1552-Week Range$0.02▼$0.78Volume210 shsAverage Volume5,210 shsMarket Capitalization$1.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware. Read More Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXS Stock News HeadlinesAyala Pharmaceuticals, Inc. (ADXS) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comRockville's OS Therapies acquires rights to key drugs, eyes FDA approval for cancer therapyFebruary 5, 2025 | bizjournals.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.August 2 at 2:00 AM | InvestorPlace (Ad)OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to PipelineJanuary 29, 2025 | businesswire.comAyala unit expands cold storage networkSeptember 4, 2024 | msn.comAyala explores minority stake sale in AC Health, sources sayAugust 1, 2024 | msn.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsMay 9, 2024 | globenewswire.comImmunome: An Oncology Powerhouse In The MakingApril 2, 2024 | seekingalpha.comSee More Headlines ADXS Stock Analysis - Frequently Asked Questions How have ADXS shares performed this year? Ayala Pharmaceuticals' stock was trading at $0.0270 on January 1st, 2025. Since then, ADXS shares have increased by 48.5% and is now trading at $0.0401. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Thursday, September, 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The company earned $0.25 million during the quarter. How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Acasti Pharma (ACST), Bristol Myers Squibb (BMY) and Company Calendar Last Earnings9/09/2021Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXS CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$3.24 million Price / Sales0.53 Cash FlowN/A Price / Cash FlowN/A Book Value($2.06) per share Price / Book-0.02Miscellaneous Outstanding Shares42,633,000Free Float42,364,000Market Cap$1.71 million OptionableNot Optionable Beta1.17 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:ADXS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.